ALZN
ALZN
NASDAQ · Biotechnology

Alzamend Neuro Inc

$1.07
+0.02 (+1.90%)
Financial Highlights (FY 2025)
Revenue
555.8K
Net Income
113.5K
Gross Margin
29.5%
Profit Margin
20.4%
Rev Growth
-5.3%
D/E Ratio
0.43
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 29.5% 29.5% 29.5%
Operating Margin 30.7% 31.4% 29.0%
Profit Margin 20.4% 22.4% 20.0%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 555.8K 518.1K 501.1K
Gross Profit 163.9K 152.8K 147.8K
Operating Income 170.5K 162.9K 145.3K
Net Income 113.5K 116.0K 100.3K
Gross Margin 29.5% 29.5% 29.5%
Operating Margin 30.7% 31.4% 29.0%
Profit Margin 20.4% 22.4% 20.0%
Rev Growth -5.3% +6.0% -5.8%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 2.09M 1.93M 2.25M
Total Equity 4.81M 4.86M 5.53M
D/E Ratio 0.43 0.40 0.41
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA 245.4K 221.0K 210.9K
Free Cash Flow 70.8K 77.8K 93.1K